{"DataElement":{"publicId":"3761970","version":"1","preferredName":"Progressive or Recurrent Glioblastoma Measured by Contrast Enhanced MRI Within 21 Days Start Treatment Indicator","preferredDefinition":"Indicator to signify whether or not the patient has measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment.","longName":"3761937v1.0:3506068v1.0","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"3761937","version":"1","preferredName":"Progressive or Recurrent Glioblastoma Measured by Contrast Enhanced MRI Within 21 Days Start Treatment","preferredDefinition":"A disease process that is increasing in scope or severity._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The return of a disease after a period of remission._The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)_A technique that uses radiofrequency waves and a magnet to image the body.  The images are enhanced by the addition of contrast agents which selectively intensify anatomical regions to intensify the clarity of the image for diagnostic purposes. 2005_Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._On the inside; contained in._A number with no fractional part, including the negative and positive numbers as well as zero.::21_The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"3761934v1.0:3761935v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"3761934","version":"1","preferredName":"PD Or Recurrent Disease Glioblastoma","preferredDefinition":"Cancer that is increasing in scope or severity.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:the return of a sign, symptom, or disease after a remission.:The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO) ","longName":"C35571:C37998:C38155:C3058","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCAFF9E9-8D72-2897-E040-BB89AD4348B0","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"ONEDATA","dateModified":"2013-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3761935","version":"1","preferredName":"Contrast-enhanced Magnetic Resonance Imaging Measurement Within Integer::21 Day Begin Therapeutic Procedure","preferredDefinition":"A technique that uses radiofrequency waves and a magnet to image the body.  The images are enhanced by the addition of contrast agents which selectively intensify anatomical regions to intensify the clarity of the image for diagnostic purposes. 2005:Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.:On the inside; contained in.:A number with no fractional part, including the negative and positive numbers as well as zero.::21:The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       :Have a beginning, in a temporal, spatial, or evaluative sense.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"3761935v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contrast-enhanced Magnetic Resonance Imaging","conceptCode":"C46087","definition":"A technique that uses radiofrequency waves and a magnet to image the body.  The images are enhanced by the addition of contrast agents which selectively intensify anatomical regions to intensify the clarity of the image for diagnostic purposes. 2005","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Measurement","conceptCode":"C25209","definition":"Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Within","conceptCode":"C25282","definition":"On the inside; contained in.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCAFF9E9-8D88-2897-E040-BB89AD4348B0","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"ONEDATA","dateModified":"2013-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCAFF9E9-8D99-2897-E040-BB89AD4348B0","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC Context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3335728","version":"1","longName":"Protocols","context":"ABTC","ClassificationSchemeItems":[{"publicId":"3761917","version":"1","longName":"ABTC 1202","context":"ABTC"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"}],"ReferenceDocuments":[{"name":"Does the patient have measura","type":"Preferred Question Text","description":"Does the patient have measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment?","url":null,"context":"ABTC"},{"name":"ABTC Alternate Question","type":"Alternate Question Text","description":"Does the patient have measurable, supratentorial, constrast-enchancing, progressive or recurrent high-grade glioma by MRI within 21 days of starting treatment?","url":null,"context":"ABTC"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Patients must have measurable, supratentorial contrast-enhancing progressive or recurrent glioblastoma or gliosarcoma by MRI imaging within 21 days of starting treatment","url":null,"context":"ABTC"},{"name":"ABTC 1701","type":"Alternate Question Text","description":"Does the patient have measurable, supratentorial contrast-enhancing progressive or recurrent glioblastoma or gliosarcoma by MRI imaging within 21 days of starting treatment?Â ","url":null,"context":"ABTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB19E30-740A-85DC-E040-BB89AD4308BF","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2018-08-28","changeDescription":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}